Compare ASTRAZENECA PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GLENMARK PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GLENMARK PHARMA ASTRAZENECA PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 112.7 14.1 798.4% View Chart
P/BV x 17.5 2.1 820.3% View Chart
Dividend Yield % 0.1 0.5 13.4%  

Financials

 ASTRAZENECA PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-21
GLENMARK PHARMA
Mar-21
ASTRAZENECA PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,970573 867.8%   
Low Rs2,348195 1,202.4%   
Sales per share (Unadj.) Rs325.4387.8 83.9%  
Earnings per share (Unadj.) Rs37.334.4 108.6%  
Cash flow per share (Unadj.) Rs45.450.1 90.6%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Avg Dividend yield %0.10.7 8.4%  
Book value per share (Unadj.) Rs181.8249.6 72.8%  
Shares outstanding (eoy) m25.00282.17 8.9%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x11.21.0 1,135.7%   
Avg P/E ratio x98.011.2 877.8%  
P/CF ratio (eoy) x80.67.7 1,052.2%  
Price / Book Value ratio x20.11.5 1,308.0%  
Dividend payout %5.47.3 73.7%   
Avg Mkt Cap Rs m91,478108,353 84.4%   
No. of employees `000NANA-   
Total wages/salary Rs m2,19523,437 9.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m8,136109,439 7.4%  
Other income Rs m128502 25.6%   
Total revenues Rs m8,264109,941 7.5%   
Gross profit Rs m1,35521,289 6.4%  
Depreciation Rs m2014,436 4.5%   
Interest Rs m113,531 0.3%   
Profit before tax Rs m1,27113,825 9.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3384,124 8.2%   
Profit after tax Rs m9339,701 9.6%  
Gross profit margin %16.719.5 85.6%  
Effective tax rate %26.629.8 89.1%   
Net profit margin %11.58.9 129.4%  
BALANCE SHEET DATA
Current assets Rs m6,88773,596 9.4%   
Current liabilities Rs m3,73442,010 8.9%   
Net working cap to sales %38.828.9 134.3%  
Current ratio x1.81.8 105.3%  
Inventory Days Days457 680.2%  
Debtors Days Days3886 44.6%  
Net fixed assets Rs m1,85567,093 2.8%   
Share capital Rs m50282 17.7%   
"Free" reserves Rs m4,49670,148 6.4%   
Net worth Rs m4,54670,430 6.5%   
Long term debt Rs m038,888 0.0%   
Total assets Rs m8,742140,689 6.2%  
Interest coverage x117.64.9 2,392.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.8 119.6%   
Return on assets %10.89.4 114.8%  
Return on equity %20.513.8 149.0%  
Return on capital %28.215.9 177.6%  
Exports to sales %00-   
Imports to sales %29.30-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m2,382NA-   
Fx inflow Rs m31835,753 0.9%   
Fx outflow Rs m2,38212,023 19.8%   
Net fx Rs m-2,06423,729 -8.7%   
CASH FLOW
From Operations Rs m1,04811,312 9.3%  
From Investments Rs m1,730-6,752 -25.6%  
From Financial Activity Rs m-90-4,418 2.0%  
Net Cashflow Rs m2,688278 966.4%  

Share Holding

Indian Promoters % 0.0 46.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.5 35.0 9.9%  
FIIs % 2.4 25.9 9.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.0 53.4 46.9%  
Shareholders   66,444 329,870 20.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   MANGALAM DRUGS  KAMRON LABORATORIES  DISHMAN CARBOGEN AMCIS  ORCHID PHARMA  JUBILANT PHARMOVA   



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Slumped 1,688 Points Today(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended deep in the red.

Related Views on News

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 45.0% (Quarterly Result Update)

Aug 11, 2021 | Updated on Aug 11, 2021

For the quarter ended June 2021, ASTRAZENECA PHARMA has posted a net profit of Rs 102 m (down 45.0% YoY). Sales on the other hand came in at Rs 2 bn (down 9.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY21); Net Profit Up 184.8% (Quarterly Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

For the quarter ended March 2021, ASTRAZENECA PHARMA has posted a net profit of Rs 273 m (up 184.8% YoY). Sales on the other hand came in at Rs 2 bn (up 7.9% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime(Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 26, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - CHANDRA BHAGAT PHARMA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS